Search clinical trials for: Linagliptin/metformin FDC

Total 5637 results

AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

Diabetes Mellitus

United States
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Type 2 Diabetes Mellitus

United States, Brazil, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Turkey, United Kingdom, South Africa, Argentina, Canada, Germany, Hungary, Israel, Romania, Slovakia, India, Belgium, France, Puerto Rico
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
Population Health Research Institute
Merck Sharp & Dohme LLC

Completed

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)

Type 2 Diabetes Mellitus

Canada
Beni-Suef University
Minia University

Completed

Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Egypt
AstraZeneca
Parexel

Completed

Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components

Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)

Germany
Boehringer Ingelheim

Completed

Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects

Healthy
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
Galenicum Health

Completed

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.

Diabetes Mellitus, Type 2 | Bioequivalence

Mexico
Merck Sharp & Dohme LLC

Completed

Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)

Type 2 Diabetes Mellitus
AstraZeneca

Withdrawn

BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

Type 2 Diabetes

Brazil
Assistance Publique Hopitaux De Marseille

Completed

Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics

Obesity | Diabetes

France
Merck Sharp & Dohme LLC

Completed

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Diabetes Mellitus | Type 2 Diabetes
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
George Medicines PTY Limited
The George Institute; Brandon Biocatalyst

Not yet recruiting

Polypill Versus Metformin in New Onset Type 2 Diabetes (PiVOT)

Type 2 Diabetes
University of Texas Southwestern Medical Center

Completed

Preservation of Beta-cell Function in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Impact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes (IMPACT-1D)

Type 1 Diabetes | Peripheral Arterial Calcification

France
GlaxoSmithKline

Completed

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany, Mexico, Peru, Russian Federation, United Kingdom, Philippines, South Africa, Spain, Hong Kong, Albania
Takeda

Terminated

Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Ukraine, Poland, Malaysia, Canada, Peru, Philippines, Hungary, Russian Federation, South Africa, Argentina, Croatia, Thailand
GL Pharm Tech Corporation

Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)

Healthy

Korea, Republic of
University of Oklahoma
VA Office of Research and Development

Terminated

Transcranial Direct Current Stimulation, Improve Functional Motor Recovery, Affected Arm

Brain Ischemia | Brain Infarction

United States
GL Pharm Tech Corporation

Completed

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers

Healthy

Korea, Republic of
Janssen Research & Development, LLC

Completed

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

Diabetes Mellitus, Type 2

United States, Poland, Colombia, Mexico, Portugal, Bulgaria, India, Malaysia, Turkey, Ukraine, Greece, Sweden, Singapore, Czech Republic, Argentina, Puerto Rico, Russian Federation, Thailand, Slovakia, Latvia, Estonia, Peru
Shandong Suncadia Medicine Co., Ltd.

Completed

A HR20031 FE Study on Healthy Subjects

Type 2 Diabetes

China
Shandong Suncadia Medicine Co., Ltd.

Active, not recruiting

A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers

Type II Diabetes

China
Michael A. Nauck

Completed

Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis

Diabetes

Germany
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)

Type 2 Diabetes Mellitus
JW Pharmaceutical

Completed

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone (CWP-DIANA-302)

Type 2 Diabetes Mellitus

Korea, Republic of
Eli Lilly and Company

Terminated

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (IMPERIUM)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Germany, United Kingdom, Austria
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

Diabetes Mellitus, Type II
Hoffmann-La Roche

Completed

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

Diabetes Mellitus Type 2

United States, France, Switzerland, Germany, South Africa, Korea, Republic of, Puerto Rico, Canada, Taiwan, Spain, Poland, Slovakia, Thailand, Mexico, Turkey, Australia, Greece, Norway, Sweden, Peru, Romania, Argentina, United Kingdom
Boehringer Ingelheim

Completed

Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers

Healthy
Jagiellonian University

Active, not recruiting

dataBase for Analysis of Rectal Cancer Oncological Results (BARO)

Rectal Cancer | Lymph Node Metastases | Metformin | Overall Survival | Disease-free Survival

Poland
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

Type 2 Diabetes
SK Chemicals Co., Ltd.

Completed

A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

Healthy Subjects

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)

Type 2 Diabetes Mellitus
AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

Diabetes Mellitus

United States
Eli Lilly and Company

Terminated

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Puerto Rico, Greece, Taiwan
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

Type 2 Diabetes Mellitus
Sanofi

Completed

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

Type 2 Diabetes Mellitus

Brazil, Peru, United States, Australia, Canada, Chile, Germany, Guatemala, Mexico, Poland, Romania, Russian Federation, Ukraine
Novartis Pharmaceuticals

Completed

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Korea, Republic of, Latvia, Peru, Lithuania, Israel, Norway, Finland, Argentina, Austria, Belgium, Germany, Greece, Guatemala, Hungary, India, Italy, Mexico, Poland, Romania, Slovakia, Venezuela
Institut National de la Santé Et de la Recherche...

Completed

Study of the Effect of Transcranial Stimulations in Aphasic Subject Within a Year of Their Stroke

Stroke | Aphasia

France
Wroclaw Medical University

Completed

Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients.

PreDiabetes | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)

Poland
Anji Pharma

Suspended

Investigational Study of Delayed Release Metformin (DREAM-T2D)

Diabetes Mellitus, Type 2

Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
Fasa University of Medical Sciences
Shiraz University of Medical Sciences

Completed

Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

Polycystic Ovary Syndrome

Iran, Islamic Republic of
Rush University Medical Center

Withdrawn

Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit

Type 2 Diabetes Mellitus

3

Subscribe